Astellas and Pfizer's XTANDI shows long-term survival benefit in prostate cancer

Astellas Pharma and Pfizer have released five-year follow-up data from the Phase 3 ARCHES trial for metastatic hormone-sensitive prostate cancer (mHSPC). The results indicate that XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduced the risk of death by 30% compared to placebo plus ADT.

At the five-year mark, 66% of patients receiving XTANDI plus ADT were alive, compared to 53% in the placebo group. XTANDI is the first and only androgen receptor inhibitor to demonstrate a five-year overall survival benefit in this patient population. The long-term data reinforce XTANDI's established role as a standard of care for mHSPC.

The treatment demonstrated consistent benefits across various patient subgroups, including those with high-volume disease. No new safety signals were identified during the five-year follow-up, and reported adverse events were in line with previous analyses.

These long-term findings support the use of XTANDI as the standard of care for treating metastatic hormone-sensitive prostate cancer. The data are being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.